VITURA HEALTH LIMITED (VIT)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

VIT - VITURA HEALTH LIMITED

Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0.06
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.16

15 Apr
2024

-0.015

OPEN

$0.18

-8.57%

HIGH

$0.18

264,484

LOW

$0.16

TARGET
$0.70 337.5% upside
Franking for last dividend paid out: 100%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
VIT: 1
Title FY22
Actual
FY23
Actual
FY24
Forecast
FY25
Forecast
EPS (cps) xxx N/A 3.0 xxx
DPS (cps) xxx N/A 1.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 5.3 xxx
Dividend Yield xxx N/A 6.3% xxx
Div Pay Ratio(%) xxx N/A 33.3% xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

5.71

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

Tell Me The Dividend After This Many Years

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - ex-div 1c (franking 100%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx2.5
DPS All xxxxxxxxxxxxxxx1.0
Sales/Revenue xxxxxxxxxxxxxxx117.3 M
Book Value Per Share xxxxxxxxxxxxxxx6.3
Net Operating Cash Flow xxxxxxxxxxxxxxx9.7 M
Net Profit Margin xxxxxxxxxxxxxxx11.77 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx45.22 %
Return on Invested Capital xxxxxxxxxxxxxxx41.41 %
Return on Assets xxxxxxxxxxxxxxx30.77 %
Return on Equity xxxxxxxxxxxxxxx45.22 %
Return on Total Capital xxxxxxxxxxxxxxx59.02 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx3.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx19 M
Price To Book Value xxxxxxxxxxxxxxx8.19

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.9 M
Capex % of Sales xxxxxxxxxxxxxxx0.79 %
Cost of Goods Sold xxxxxxxxxxxxxxx91 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

19/09/2023

1

Buy

$0.70

337.50%

Bell Potter notes prescribing activity has surged in August. SAS-B applications, mostly used by new prescribers of medicinal cannabis, in August totalled 15,400 applications, significantly ahead of previous monthly averages.

The Authorised Prescriber path, used by clinicians with greater prescribing experience, was also significantly higher during the month, at 2300 applications.

While there are an increasing number of smaller distributors in the segment, the broker notes Vitura Health has significant market share and is well-positioned to capture industry growth.

The broader integration of CanView 2.0 among prescribers will also be critical to sustaining growth in FY24. Buy rating and $0.70 target unchanged.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 1.00 cents and EPS of 3.00 cents.
Bell Potter forecasts a full year FY25 dividend of 1.00 cents and EPS of 3.60 cents.

VIT STOCK CHART